Hikma and Vectura disappointed by FDA’s generic Advair response

After receiving an unfavourable verdict from US drug regulators, Hikma Pharamceuticals and partner Vectura felt there was a “low likelihood” that their generic version of asthma treatment Advair would be approved this year.

Sourced through Scoop.it from: www.digitallook.com

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s